LUTS: Lower Urinary Tract Symptoms最新文献

{"title":"Barriers to Seeking Medical Consultation for Urinary Incontinence: A Nationwide Population-Based Study in Saudi Arabia","authors":"Ebtesam Almajed,&nbsp;Norah Alqntash,&nbsp;Badriyah AlDejain,&nbsp;Noura AlQurashi,&nbsp;Mohammed Alshehri,&nbsp;Ali AbdelRaheem,&nbsp;Nojoud Alamri","doi":"10.1111/luts.70033","DOIUrl":"https://doi.org/10.1111/luts.70033","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Urinary incontinence (UI) is prevalent and often underreported due to various barriers affecting healthcare-seeking behavior. This study aimed to identify barriers preventing patients from seeking help for UI, assess the influence of sociodemographic and clinical factors on these barriers, and determine the associations between UI types and barriers in Saudi Arabia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A nationwide, cross-sectional study was conducted from June 2024 to April 2025 among individuals aged ≥ 18 years who experienced UI and had not sought medical consultation. Participants completed a questionnaire that comprised sociodemographic data, the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF), and a modified Barriers to Incontinence Care Seeking Questionnaire (BICS-Q). Data were analyzed using descriptive statistics, independent <i>t</i>-tests, ANOVA, and binary logistic regression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 505 eligible participants, 80.6% were female, predominantly aged 31–45 (40.0%), and the most common UI type was mixed UI (37.2%). The most significant barriers were embarrassment (33.3%), logistical inconvenience (appointments scheduled too far in advance, 36.8%), and provider-related issues (lack of available providers, 12.3%). Gender, obesity, residency region, and type of UI significantly influenced barrier perception. Fear-related barriers were notably higher in nocturnal UI, whereas embarrassment and cultural concerns were highest among those with mixed UI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study highlights significant embarrassment, inconvenience, and provider-related barriers deterring healthcare-seeking among UI patients in Saudi Arabia. Findings emphasize the need for culturally tailored interventions, improved healthcare accessibility, and targeted public awareness campaigns.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/luts.70033","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145272757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selective Bladder Denervation via Radiofrequency Ablation Versus Intravesical Onabotulinum Toxin A for Refractory Overactive Bladder: The Short-Term Results of A Preliminary Randomized Controlled Trial","authors":"Salih Zeki Sönmez,&nbsp;İsmail Ulus,&nbsp;Aykut Çolakerol,&nbsp;Mustafa Zafer Temiz,&nbsp;Enes Pay,&nbsp;Muhammet Murat Dinçer","doi":"10.1111/luts.70032","DOIUrl":"10.1111/luts.70032","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Overactive bladder (OAB) is a prevalent and burdensome condition associated with significant impairments in health-related quality of life and substantial healthcare costs. While third-line therapies such as intravesical onabotulinum toxin A (BTA) and sacral neuromodulation are established treatment options for refractory cases, selective bladder denervation (SBD) via radiofrequency ablation (RFA) has emerged as a novel minimally invasive alternative. This study aimed to prospectively compare the efficacy and safety of SBD versus BTA in women with refractory OAB.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this randomized controlled trial, 54 women with refractory OAB were allocated to receive either SBD or BTA. Patients were followed for 12 weeks and assessed for changes in urgency episodes, urgency urinary incontinence (UUI), daily voiding frequency, overactive bladder symptom scores (OAB-V8), quality of life (I-QOL), post-void residual (PVR) volume, and treatment-emergent adverse events.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Both interventions resulted in significant symptom improvement relative to baseline (<i>p</i> &lt; 0.05). However, BTA demonstrated superior therapeutic efficacy, with a significantly higher proportion of patients achieving ≥ 50% reductions in urgency and UUI episodes across all follow-up visits (<i>p</i> &lt; 0.05). Additionally, BTA yielded greater improvements in symptom scores and quality of life indices. Adverse events were infrequent and mild in both groups. The BTA group exhibited a transient increase in PVR at early follow-up, though no cases of acute urinary retention necessitating catheterization were observed. The SBD group showed modest symptom relief with stable objective parameters.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In this prospective randomized trial, intravesical BTA provided superior clinical efficacy compared to SBD across both subjective and objective outcome measures in women with refractory OAB. While SBD may represent a minimally invasive option for select patient populations, BTA remains the more effective third-line intervention. Further large-scale, sham-controlled studies with longer follow-up are warranted to clarify the role of SBD and optimize patient selection.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145131202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urodynamic Risk Factors for Recurrent Febrile Graft Pyelonephritis in Kidney Transplant Recipients: A Retrospective Study","authors":"Jun Kamei,&nbsp;Ei-ichiro Takaoka,&nbsp;Takehiro Ohyama,&nbsp;Sho Nishida,&nbsp;Daiji Watanabe,&nbsp;Aya Niimi,&nbsp;Yuta Yamada,&nbsp;Toru Sugihara,&nbsp;Satoshi Ando,&nbsp;Haruki Kume,&nbsp;Daiki Iwami,&nbsp;Tetsuya Fujimura","doi":"10.1111/luts.70031","DOIUrl":"https://doi.org/10.1111/luts.70031","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>We aimed to assess lower urinary tract function and morphological changes in kidney transplant recipients with a history of graft pyelonephritis and investigate the association between specific types of lower urinary tract dysfunction and the risk of recurrent graft pyelonephritis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively reviewed the medical records of kidney transplant recipients hospitalized for febrile graft pyelonephritis more than 1 year after transplantation between April 2019 and October 2023. Patients underwent cystography and urodynamic studies after infection control and were followed up for at least 12 months. They were classified based on urodynamic findings, and recurrence-free survival was analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty-four patients were included. Vesicoureteral reflux of the grafted kidney was observed in 20 (83.3%) patients. Detrusor overactivity, detrusor underactivity, and low-compliance bladders were diagnosed in 8 (33.3%), 12 (50.0%), and 7 (29.2%) patients, respectively. Based on urodynamic findings, treatment and bladder management were modified in 20 patients. During a median follow-up of 33 months, seven patients developed recurrent graft pyelonephritis. Detrusor overactivity remained an independent risk factor for recurrent graft pyelonephritis (odds ratio, 21.4; <i>p =</i> 0.04). Patients with detrusor overactivity or underactivity but not low-compliance bladder had significantly shorter recurrence-free survival compared with those without these dysfunctions (<i>p</i> = 0.017, 0.038, and 0.38, respectively).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Persistent lower urinary tract dysfunction, particularly detrusor overactivity, is a significant risk factor for recurrent graft pyelonephritis. Comprehensive evaluation of vesicoureteral reflux and lower urinary tract function via urodynamic studies is important to improve posttransplant outcomes in patients with a history of graft pyelonephritis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/luts.70031","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prescription Trends of Initial Pharmacotherapy for Benign Prostatic Hyperplasia Among Treatment-Naïve Patients in South Korea: A Retrospective Analysis","authors":"Yeon Hee Kim,&nbsp;Nam Kyung Je","doi":"10.1111/luts.70030","DOIUrl":"https://doi.org/10.1111/luts.70030","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Benign prostatic hyperplasia (BPH) is a common urological condition in aging men that causes lower urinary tract symptoms. Pharmacotherapy is central to BPH management; however, considering updated guidelines, recent prescription trends remain insufficiently explored. This study aimed to assess initial pharmacotherapy trends in patients newly diagnosed with BPH.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cross-sectional analysis used 2015–2020 data from the Health Insurance Review and Assessment Service to examine the trends and influencing factors of BPH drug utilization among South Korean patients aged ≥ 40 years with no prior history of BPH. Subgroup analyses were performed by categorizing patients into five age groups (40–49, 50–59, 60–69, 70–79, and ≥ 80 years) to evaluate age-specific prescription patterns.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 1,445,144 patients newly diagnosed with BPH, 1,336,695 (92.4%) initiated treatment within 60 days of diagnosis. Among those treated, 54.9% received α-blocker (AB) monotherapy and 17.9% received 5α-reductase inhibitor (5-ARI)/AB combinations. Use of 5-ARI/AB combinations increased with age, from 8.0% in patients in their 40s to 25.4% in those aged ≥ 80 years. Tamsulosin (a selective AB), dutasteride (a 5-ARI), and mirabegron (a β3-agonist) were the most frequently prescribed agents.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Recent American Urological Association (AUA) guidelines recommend combination therapy as an effective strategy for reducing the risk of BPH-related complications. Although the largest proportion of patients was prescribed AB monotherapy, the growing adoption of combination therapy in South Korea, particularly among older age groups, suggests a shift toward more guideline-concordant and effective therapeutic approaches.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/luts.70030","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144990702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comparison of Spinal Alignment and Trunk Mobility in Parkinson's Disease Patients With and Without Lower Urinary Tract Symptoms","authors":"Betül Kuz,&nbsp;Mustafa Ertuğrul Yaşa,&nbsp;Rıza Sonkaya,&nbsp;Selman Aktaş","doi":"10.1111/luts.70028","DOIUrl":"https://doi.org/10.1111/luts.70028","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Lower urinary tract symptoms (LUTS) in Parkinson's disease (PD) primarily result from neurological abnormalities. Yet, the impact of postural abnormalities and muscular rigidity on lower urinary tract symptoms remains unclear. This study aims to compare spinal alignment and trunk mobility in PD patients with and without LUTS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 93 patients were included in this cross-sectional study. Two groups were created based on the presence of LUTS. The study was completed with 57 symptomatic and 36 asymptomatic patients. The presence of LUTS was determined using the International Prostate Symptom Score. The Urinary Symptom Profile questionnaire was used for LUTS classification. Spinal posture and trunk mobility were measured using the Spinal Mouse.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared to the asymptomatic controls, decreased lumbar lordosis (<i>p</i> = 0.022) and increased anterior trunk tilt (<i>p</i> = 0.026) were evident in symptomatic patients. However, no significant differences were found in thoracic kyphosis or lateral spinal curvatures (<i>p</i> &gt; 0.05). Asymptomatic patients demonstrated greater lumbar mobility and total trunk mobility in both the sagittal plane (<i>p</i> = 0.002; <i>p</i> = 0.023) and the frontal plane (<i>p</i> = 0.024; <i>p</i> = 0.046), respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>PD patients with LUTS demonstrate distinct alterations in spinal alignment and trunk mobility compared to those without symptoms. These biomechanical differences may reflect compensatory mechanisms or additional motor involvement contributing to urinary dysfunction in this population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144929819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic Immune-Inflammation Index and Neutrophil-To-Lymphocyte Ratio: U-Shaped Association With Overactive Bladder","authors":"Qinglong Yang,&nbsp;Haolin Chen,&nbsp;Hanyuan Lin,&nbsp;Haoxian Tang,&nbsp;Nan Luo,&nbsp;Xuan Zhang,&nbsp;Jingtao Huang,&nbsp;Xuxia Sui,&nbsp;Qingtao Yang","doi":"10.1111/luts.70029","DOIUrl":"https://doi.org/10.1111/luts.70029","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aims to examine the association of systemic immune-inflammation index (SII) and neutrophil-to-lymphocyte ratio (NLR) with the prevalence of overactive bladder (OAB).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cross-sectional study analyzed data from 22,343 participants (≥ 20 years) in the National Health and Nutrition Examination Survey (2005–2018). We applied weighted multivariate logistic regression, restricted cubic spline (RCS) regression, subgroup, and sensitivity analyses to assess the associations between SII, NLR, and OAB.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>RCS analysis revealed U-shaped relationships with inflection points at 6.13 for ln(SII) and 0.65 for ln(NLR). In the fully adjusted model, ln(SII) ≤ 6.13 showed a negative correlation with OAB (OR = 0.83; 95% CI: 0.70–0.99), while ln(SII) &gt; 6.13 was positively correlated (OR = 1.32; 95% CI: 1.10–1.58). Similarly, ln(NLR) &gt; 0.65 correlated positively with OAB (OR = 1.40; 95% CI: 1.16–1.71). Subgroup analyses revealed significant differences in alcohol use subgroups for ln(SII) ≤ 6.13 and ln(NLR) ≤ 0.65 (<i>P</i> for interaction &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>SII and NLR may serve as biomarkers for assessing OAB risk.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144935336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Lower Urinary Tract Symptoms on Daily Life in Individuals With Co-Existence Overactive and Underactive Bladder, Overactive Bladder, and Underactive Bladder","authors":"Noritoshi Sekido,&nbsp;Kenji Omae,&nbsp;Nobuhiro Haga,&nbsp;Yasue Kubota,&nbsp;Motoaki Saito,&nbsp;Ryuji Sakakibara,&nbsp;Mikako Yoshida,&nbsp;Takahiko Mitsui,&nbsp;Naoya Masumori,&nbsp;Satoru Takahashi","doi":"10.1111/luts.70026","DOIUrl":"https://doi.org/10.1111/luts.70026","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To explore the particular lower urinary tract symptoms (LUTS) that impact daily life in co-existent overactive and underactive bladder (COUB), overactive bladder (OAB), and underactive bladder (UAB) as symptom syndromes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using data from a nationwide, cross-sectional internet survey of adults aged ≥ 20 conducted in Japan, participants were categorized into COUB, OAB alone, UAB alone, and non-OAB/UAB groups according to the OAB symptom score and the provisional UAB definition of the International Continence Society working group. Participants were asked what symptoms affected their daily lives. The prevalence of LUTS and the particular LUTS affecting daily life were evaluated in each group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Substantial proportions of participants in all groups had increased daytime frequency and nocturia. Even in the male OAB alone group, the prevalence of voiding symptoms was substantial. In almost all of the groups, storage symptoms accounted for more than approximately 80% of the particular LUTS that had the greatest impact on daily life, and nocturia ranked first, except for the male OAB alone group, with a 32% rate of urgency.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Although multiple LUTS affected daily life in individuals with COUB and UAB, storage symptoms, particularly nocturia, are likely to have the greatest impact of LUTS on daily life in those not only with OAB but also with UAB and COUB.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/luts.70026","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144810939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the Antihyperplastic, Anti-Inflammatory and Antioxidant Properties of Cucurbita Pepo L. Seed Oil on Testosterone- Induced Benign Prostatic Hyperplasia (BPH) in Castrated Rat Model","authors":"Hajji Noura,&nbsp;Khémiri Ikram","doi":"10.1111/luts.70024","DOIUrl":"https://doi.org/10.1111/luts.70024","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The present study investigates the therapeutic potential of <i>Cucurbita Pepo</i> L. Seeds' Oil (CPSO) extracted by petroleum ether on testosterone-induced hyperplasia (BPH) in a castrated Wistar rat model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Animals underwent two stages of treatment (28 days each): the testosterone treatment stage, to promote BPH, and the therapeutic stage, which consisted of an oral administration of CPSO. Forty-eight Wistar rats were equally divided into six groups: the negative control; groups 2–6 underwent a bilateral orchidectomy (induced via the scrotal route), then were redistributed into the castrated-control group and the castrated and testosterone-treated groups BPH induction (10 mg/kg). Twenty-eight days after BPH induction, the BPH rats were orally treated with Finasteride (FINA group: 5 mg/kg/d) and CPSO (CPSO-1 group: 40 mg/kg/d; CPSO-2 group: 80 mg/kg/d) for 28 additional days. Plasma biochemical parameters, circulating testosterone (T) and prostate-specific antigen (PSA), prostate oxidative markers, and inflammation were analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>CPSO administration exhibited a decrease in prostate weight, normalized the plasma total proteins, lipids, calcium and glucose, testosterone, and PSA levels, and attenuated the disturbances of liver and kidney functions in BPH rats. At the prostate level, CPSO showed a notably decreased prostate oxidation and inflammation. The histological study showed that CPSO restored prostatic lesions caused by BPH.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>According to the present results, we suggest that CPSO could have a protective potential related to its proven anti-oxidant, anti-hyperplastic, and anti-inflammatory properties on preventing testosterone-induced BPH in castrated rats and might be used as an herbal remedy or nutraceutical agent in BPH management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144773644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological Targeting of Hyperpolarization-Activated Cyclic Nucleotide-Gated Cation Channels on Bladder Afferent Sensory Transmission","authors":"Eric Woon,&nbsp;Jorge Villalobos Santeli,&nbsp;Jia Liu,&nbsp;Longtu Chen,&nbsp;George Kuchel,&nbsp;Bin Feng","doi":"10.1111/luts.70025","DOIUrl":"https://doi.org/10.1111/luts.70025","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to investigate the potential role of cesium chloride (CsCl), ivabradine (IVA), and isoproterenol (ISO) on the sensory transmission of bladder afferents to graded urinary bladder distension (UBD). We specifically selected these drugs to target the hyperpolarization-activated cyclic nucleotide-gated (HCN) cation channels to determine their role in afferent encoding.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The bladders of C57BL/6 female mice were harvested with attached pelvic nerves in continuity, and the stimulus–response function (SRF) of bladder afferents to stepped bladder distension (20, 40, 60, 80 cmH₂O) was recorded by single-fiber recordings. Their changes in SRF to bath application of CsCl, IVA, and ISO were then evaluated. The presence of HCN on bladder afferent endings was assessed through immunohistological staining on bladder sections from mice with genetically labeled bladder afferents.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>IVA and ISO did not significantly reduce afferent responses to UBD, whereas CsCl increased afferent responses. Bladder afferents in the pelvic nerve pathway were categorized into low-firing (LF, &lt; 10 Hz) and high-firing (HF, &gt; 10 Hz) groups. SRF in both the LF and HF groups showed similar trends with no significant changes in response to IVA and ISO. CsCl increased SRF only in the HF group but not in the LF group. Immunohistological staining revealed that HCN1 does not extensively co-localize with afferent endings, showing only sporadic presence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our targeted pharmacological studies with single-fiber recordings and immunohistological staining collectively suggest that HCN channels do not play a significant role in bladder afferent sensory transmission.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/luts.70025","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144773643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tolerability and Efficacy of Duloxetine Compared to Amitriptyline in Women With Chronic Pelvic Pain Syndrome: Findings From a Clinical Trial","authors":"Maede Mohseni,&nbsp;Rojan Ghaderzadeh,&nbsp;Kimia Bakhtiari,&nbsp;Maryam Zamanirafe,&nbsp;Mona Doostizadeh,&nbsp;Aliasghar Tabatabaeii Mohammadi,&nbsp;Kiumarth Amini,&nbsp;Maryam Mehrpooya","doi":"10.1111/luts.70023","DOIUrl":"https://doi.org/10.1111/luts.70023","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Duloxetine has demonstrated efficacy in treating various types of chronic pain conditions. A double-blind clinical trial was conducted to assess the effectiveness and tolerability of duloxetine compared to amitriptyline in women suffering from chronic pelvic pain (CPP) syndrome.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Sixty-nine eligible women diagnosed with CPP syndrome were randomly assigned to receive either duloxetine or amitriptyline. Duloxetine was initiated at 30 mg/day and amitriptyline at 25 mg/day, with dosages increased to 60 mg/day for duloxetine and 50 mg/day for amitriptyline after the first week and maintained throughout weeks 2 to 8 of the treatment phase. The effectiveness of the treatment was assessed using the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) and its domain scores at weeks 4 and 8 after treatment. The safety and tolerability of the study medications were assessed using an antidepressant side effect checklist and spontaneous participant reports of adverse effects. All analyses were conducted on an Intention-to-Treat (ITT) analysis data set.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patients undergoing both medications experienced similar improvements in their total NIH-CPSI scores at weeks 4 and 8. The proportions of patients achieving a response, defined as at least a 6-point reduction in the total NIH-CPSI score at both weeks 4 and 8, were also comparable between the duloxetine and amitriptyline treatments. Further, at the end of the study period, a similar proportion of subjects reported marked or moderate overall symptom improvements with both treatments. However, in the analysis of NIH-CPSI domain scores, duloxetine-treated patients exhibited lower pain domain scores at both study endpoints, while amitriptyline-treated patients achieved better scores in the urinary symptoms domain. Regarding quality of life domain scores, no significant differences were observed between the groups. In terms of safety and tolerability, duloxetine demonstrated more favorable outcomes, with fewer patients experiencing adverse effects and a lower withdrawal rate due to adverse effects compared to amitriptyline.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings suggest that duloxetine is as effective as amitriptyline for managing CPP syndrome in women, with the added advantage of a more favorable safety profile.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>The trial was registered at the Iranian Registry of Clinical Trials (identifie","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144714670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}